• Explore /
  • Poster
  • / SAINT: Results of an expanded phase II study using safe amounts of ipilimumab (I), nivolumab (N), and trabectedin (T) as first-line treatment of advanced soft tissue sarcoma [NCT03138161].

SAINT: Results of an expanded phase II study using safe amounts of ipilimumab (I), nivolumab (N), and trabectedin (T) as first-line treatment of advanced soft tissue sarcoma [NCT03138161].

Abstract Poster

Authors

Erlinda Gordon

Erlinda Maria Gordon

Sarcoma Oncology Research Center, Santa Monica, CA

Erlinda Maria Gordon , Victoria S. Chua-Alcala , Katherine Kim , Paul Stendahl Dy , Micaela Kristina Paz , Nicole Angel , Ania Moradkhani , Doris Quon , Steven Wong , Omid Jafari , Sant P. Chawla

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Sarcoma

Track

Sarcoma

Sub Track

Soft Tissue Tumors

Clinical Trial Registration Number

NCT03138161

Citation

J Clin Oncol 38: 2020 (suppl; abstr 11520)

DOI

10.1200/JCO.2020.38.15_suppl.11520

Abstract #

11520

Poster Bd #

408

Abstract Disclosures

Similar Posters

First Author: Erlinda Maria Gordon

First Author: Erlinda Maria Gordon

First Author: Sant P. Chawla

First Author: Erlinda Maria Gordon